SARC021C: A Continuation Study of TH-CR-406/SARC021
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
SARC021C is a nonrandomized, open-label, multicenter, continuation study designed to provide
access to TH-302 for patients currently receiving and benefiting from single agent TH-302
therapy as part of the Phase III TH-CR-406/SARC021 study.
Details
Lead Sponsor:
Sarcoma Alliance for Research through Collaboration